WP1 incorporates overall Project Coordination, Project Management, Financial Management and Risk Management for the project. This includes compilation of reports and other deliverables for submission to IMI, development of strategies and long-term project plans, […]
WP2 provides the critical clinical knowledge and patient insight needed to deliver all project objectives. The WP2 leadership will coordinate a Clinical Knowledge and Insight Task Force (CKI-TF) that will include: (i) patient partners; […]
WP3 is responsible for optimization of the selected digital devices to the project needs, facilitating the implementation and use of digital hardware devices and accompanying software (or applications) in the clinical trials. WP3 will […]
WP4 handles the analysis of data from the different digital devices and technologies used in IDEA-FAST. It involves quality checking of the collected device-specific data, assessment of natural variations in the measures, preprocessing, feature […]
The IDEA-FAST datasets are expected to be heterogeneous, large-scale and highly complex. WP5 will establish the state-of-the-art data management environment to address the needs of data standardisation, integration, sharing, analysis and archive for the […]
WP6 is responsible for the operational management of the CVS. Partner ECRIN will work closely with the Sponsor and the lead CTU (both UKSH), the clinical leads, the CKI-TF, the technology partners, WP8 (especially […]
WP7 (final fatigue/sleep endpoints) together with WP4 (deriving intermediate predictors) is responsible for the analysis of the extant datasets as well as the data from the FS and the CVS. It will perform the […]
WP8 provides the critical input to issues arise from the project in relation to the areas of data privacy/protection, legal, ethical and other relevant regulations, and ensure compliance. Patient data within IDEA-FAST is only […]
To ensure maximal impact, WP9 activities will run concurrently with the activities of WP2-7 as part of an iterative process, harnessing the substantial clinical and regulatory expertise present within IDEA-FAST through the Exploitation and […]
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.